ACM
IMGN

AlphaCrest Capital Management’s Immunogen Inc IMGN Stock Holding History

AlphaCrest Capital Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-56,700
Closed -$321K – 1467
2021
Q3 		$321K Buy
+56,700
New +$328K 0.02% 1080
2019
Q1 		– Sell
-16,300
Closed -$78K – 984
2018
Q4 		$78K Buy
+16,300
New +$98.9K 0.02% 620

Other funds holding IMGN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AlphaCrest Capital Management's IMGN Position: Q4 2021 in Review

AlphaCrest Capital Management sold out of Immunogen Inc (IMGN) in Q4 2021, closing a stake of 56,700 shares — an estimated $321K sold.

AlphaCrest Capital Management first reported a position in IMGN in Q4 2018 and held it in 2 quarters. The position peaked at $321K in Q3 2021. 236 funds tracked by Wall St. Rank hold IMGN as of Q4 2021.

  • AlphaCrest Capital Management reported no remaining Immunogen Inc position as of Q4 2021 after selling out during the quarter.
  • AlphaCrest Capital Management sold 56,700 Immunogen Inc shares in Q4 2021, an estimated $321K.
  • AlphaCrest Capital Management first reported a position in Immunogen Inc in Q4 2018 and held it in 2 quarters.
  • AlphaCrest Capital Management's Immunogen Inc position peaked at $321K in Q3 2021.
  • 236 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2021.

Based on AlphaCrest Capital Management's 13F filing for Q4 2021, filed 9 Feb 2022.